Introduction to IDWeek 2024
Theratechnologies Inc. is all set to showcase groundbreaking research at IDWeek 2024, scheduled for mid-October in Los Angeles. As a biopharmaceutical company dedicated to bringing innovative therapies to market, Theratechnologies aims to shed light on important medical advancements in HIV treatment.
Significant Findings on HIV and Cardiovascular Health
One of the poster presentations will delve into the relationship between excess visceral abdominal fat (EVAF) and the heightened cardiovascular risk experienced by individuals living with HIV. This study is crucial as it connects obesity-related health issues with the unique needs of HIV patients.
The Role of Tesamorelin
Another key presentation will evaluate the efficacy of tesamorelin, a growth hormone-releasing factor (GHRF) analog. This research investigates how tesamorelin can help reduce EVAF and, consequently, lower the cardiovascular disease risk among people with HIV. The implications of this study could be transformative for managing heart health in HIV patients.
PROMISE-US Trial Insights
A third poster will feature baseline characteristics and study design from the PROMISE-US trial. This observational study focuses on the outcomes of ibalizumab treatment in patients with multidrug resistance, particularly those heavily experienced in HIV treatment. Understanding these outcomes will offer valuable insights into effective treatment strategies in real-world settings.
Expert Voices on HIV Treatment Challenges
Dr. Christian Marsolais, Senior VP and Chief Medical Officer at Theratechnologies, highlighted the urgency of addressing these medical challenges. With advancements in HIV treatment allowing people to live longer, the associated risks such as increased visceral fat and drug resistance require more attention from healthcare professionals.
Details of the Presentations
Theratechnologies has listed three important poster presentations for IDWeek 2024:
1. Impact of Tesamorelin on Cardiovascular Disease Risk Prediction Scores in Phase 3 Studies Treatment Arms: Subanalysis
- Lead Author: Steven Grinspoon, MD, from Massachusetts General Hospital
- Date & Time: Thursday, October 17, 12:15 PM – 1:30 PM PT
- Session Title: HIV: Complications and Coinfections
- Location: Halls JK, Poster Board Number: P-433
2. Cardiovascular Risk Scores and Insulin Resistance are Higher with Excess Visceral Abdominal Fat in People with HIV in the Modern Antiretroviral (ART) Era
- Presenting Author: Karam Mounzer, MD, University of Pennsylvania
- Date & Time: Thursday, October 17, 12:15 PM – 1:30 PM PT
- Session Title: HIV: Complications and Coinfections
- Location: Halls JK, Poster Board Number: P-453
3. A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US) Study Design and Baseline Characteristics
- Presenting Author: Dr. Charlotte-Paige Rolle, M.D., Orlando Immunology Center
- Date & Time: Thursday, October 17, 12:15 PM – 1:30 PM PT
- Session Title: HIV: Treatment
- Location: Halls JK, Poster Board Number: P-565
Understanding the IDWeek Impact
IDWeek is a prominent gathering that unites numerous infectious disease organizations. It provides a platform for professionals to discuss the latest data surrounding HIV and other infectious diseases, emphasizing the importance of ongoing research and collaboration in refining treatment paradigms.
About Theratechnologies
Theratechnologies is a company committed to innovating therapies aimed at filling significant medical gaps, particularly in the area of HIV treatment. More about their latest findings can be found on their website.
Frequently Asked Questions
What is IDWeek 2024?
IDWeek 2024 is a prominent conference focusing on infectious diseases, where experts share the latest research and insights into treatment.
What are the key topics Theratechnologies will present?
They will discuss excess visceral abdominal fat, cardiovascular health risks, and outcomes related to multidrug resistance in HIV patients.
Who are the presenters for Theratechnologies at the conference?
Presenters include notable experts like Dr. Steven Grinspoon and Dr. Karam Mounzer.
Why is addressing cardiovascular health in HIV patients important?
With advancements in HIV treatment, patients are living longer, but they may face increased health risks like cardiovascular diseases.
How does Theratechnologies contribute to HIV treatment?
Theratechnologies develops innovative therapies that address unmet medical needs for individuals living with HIV.
